| 非小细胞肺癌表皮生长因子受体-酪氨酸激酶抑制剂的一线治疗 |
| |
| 引用本文： | 杨锦. 非小细胞肺癌表皮生长因子受体-酪氨酸激酶抑制剂的一线治疗[J]. 国际肿瘤学杂志, 2010, 37(3). DOI: 10.3760/cma.j.issn.1673-422X.2010.03.016 |
| |
| 作者姓名： | 杨锦 |
| |
| 作者单位： | 北京军区总医院全军肿瘤内科诊治中心,100700 |
| |
| 摘 要： | 表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)参与的晚期非小细胞肺癌(NSCLC)一线治疗的几种模式显示出不同的结果.化疗与EGFR-TKI联合未显示生存优势,化疗序贯EGFR-TKI和EGFR-TKI单药这两种模式取得了巨大的突破,为晚期NSCLC个体化治疗开辟了新的道路.同时发现EGFR突变在晚期NSCLC靶向治疗方面有很好的疗效预测价值.
|
| 关 键 词： | 癌 非小细胞肺 受体 表皮生长因子 蛋白酪氨酸激酶类 酶抑制剂 |
Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced non-small-cell lung cancer |
| |
| YANG Jin. Epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in advanced non-small-cell lung cancer[J]. Journal of International Oncology, 2010, 37(3). DOI: 10.3760/cma.j.issn.1673-422X.2010.03.016 |
| |
| Authors: | YANG Jin |
| |
| Abstract: | Several models about epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)as first-line treatment in advanced NSCLC show different results.Combination with chemotherapy and EG-FR-TKIs did not indicate survival advantage.However,sequential chemotherapy in EGFR-TKIs and a single agent of EGFR-TKIs as first-line treatment of advanced NSCLC have made tremendous breakthrough,and give a new path in individual treatment of advanced NSCLC.Also EGFR mulatious in targeted therapy of advanced NSCLc has a sood predictive value of the etticacy. |
| |
| Keywords: | Carcinoma,non-small cell lung Receptor,epidermal growth factor Protein-tyrosine kinases Enzyme inhibitors |
| 本文献已被 万方数据 等数据库收录！ |
